Vasomedical's EECP System Produces Optimal Blood Flow Changes;
System Consistently Effective; Study Reported in Clinical Cardiology
Business Wire - September 24, 1998 07:45
WESTBURY, N.Y.--(BW HealthWire)--Sept. 24, 1998--Vasomedical Inc. (Nasdaq:VASO) Thursday cited a just-published State University of New York (SUNY) study demonstrating the ability of the company's Enhanced External Counterpulsation EECP(R) system, used in treating angina and related heart conditions, to consistently generate diastolic to systolic ratios of 1.5 to 2.0, which are optimal for maximizing aortic flow changes.
The study, which was conducted at the University's Health Sciences Center in Stony Brook, N.Y., appeared this month in the medical journal Clinical Cardiology.
"This study shows that the EECP system can produce effective levels of counterpulsation at cuff pressures easily tolerated by most patients, including the elderly," commented William E. Lawson, M.D., study report author and associate director of Cardiology and chief of Catheterization Laboratories at the center.
"Our findings may help validate the consistently good clinical results achieved with EECP treatment compared to mixed results observed with previous external counterpulsation designs."
Previous clinical tests of counterpulsation in coronary heart disease reflected dependence on high diastolic to systolic pressure ratios. Older single or two-stage compression systems failed to raise diastolic and lower systolic meaningfully, thus limiting the overall utility of external counterpulsation. The SUNY study demonstrated that EECP's three-stage sequenced compression successfully obtained consistent and effective counterpulsation ratios without excessive pressures, unlike older systems.
Vasomedical Inc. (www.vasomedical.com) is primarily engaged in designing, manufacturing, marketing and supporting external
counterpulsation systems based on the company's proprietary technology. EECP is a registered trademark of Vasomedical. Vasomedical's EECP system is now in use at major medical centers, including the Columbia-Presbyterian Medical Center, the University of Pittsburgh, The Miami Heart Institute and the University of California at San Diego and San Francisco, for the treatment of coronary heart disease. The company provides hospitals, clinics and private practices EECP equipment, treatment guidelines and a staff training and maintenance program to ensure optimal patient outcomes.
Except for historical information contained in this news release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements.
Such forward-looking statements are based on the beliefs of the company's management, as well as assumptions made by and information currently available to the company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the company's SEC reports.
CONTACT: Allen & Caron Inc.
Mark Alvino (investors)
212/698-1360
Owen Daley (media)
714/957-8440
or
Vasomedical Inc.
Anthony E. Peacock, 516/997-4600, Ext. 120
|
